VIP (Vasoactive Intestinal Polypeptide)
Vasoactive Intestinal Peptide · Neuropeptide
Overview
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering…
VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion,…
VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity.
Dilates peripheral blood vessels through NO-dependent mechanisms above 100 pmol doses.
Coronary vasodilation with positive inotropic and chronotropic effects on the heart.
Mechanism
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering…
VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion,…
VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity.
Research areas
- Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering…
- VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion,…
- VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity.
- Dilates peripheral blood vessels through NO-dependent mechanisms above 100 pmol doses.
- Coronary vasodilation with positive inotropic and chronotropic effects on the heart.
Research notes
- Vasodilation (flushing, warmth)
- Gastrointestinal effects (diarrhea possible)
- Allergic reaction symptoms
- VIPoma or related tumors
- Pregnancy or breastfeeding
Questions
Does VIP cause dangerous hypotension or can it be used safely in most patients?
VIP's vasodilation can cause hypotension and flushing, especially at higher doses. Careful dose titration and patient monitoring are essential. Patients with baseline hypotension or severe cardiac conditions should avoid use, but mild transient vasodilation is manageable in most populations with proper medical…
Can VIP improve insulin secretion for diabetes without causing hypoglycemia?
Yes, VIP promotes glucose-dependent insulin secretion via VPAC2 receptors, meaning it only stimulates insulin when blood glucose is elevated. This glucose-dependent mechanism makes hypoglycemia risk very low compared to other insulin secretagogues, making VIP theoretically safer for diabetes support.